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Ambulatory blood pressure in microalbuminuric type I diabetic pa.
tients. Twenty-four-hour ambulatory blood pressure (AMBP) was per-
formed in microalbuminuric (micro.) type I diabetic patients, with the
aim of comparison with a matched group of normoalbuminuric patients
(normo.) and healthy controls. Thirty-four patients without antihyper-
tensive medication were investigated in each group. Urinary albumin
excretion (UAE) for micro. was (geometric mean, tolerance factor
tg/min) 51.7 x/÷ 1.94, 5.1 x/÷ 1.88 for normo. and 5.2 ></÷ 1.75 for
controls. Twenty-four-hour AMBP (mean systolic/diastolic mm Hg
SD) was significantly higher in micro. (131 10/78 7) than in normo.
(122 8/73 6; P < 0.001/P < 0.01). No 24-hour AMBP difference
between normo. and controls (120 9/71 7) was found. No difference
in the night/day ratio of blood pressure was found between the diabetic
groups. Coefficient of variation for day time systolic measurements did
not show any intergroup difference. Systolic day time blood pressure
for the pooled diabetic group correlated significantly with UAE (r
0.45, P < 0.001), whereas no significant correlation with auscultatory
systolic values in the clinic was found (r = 0.21; P = 0.09). In
conclusion, blood pressure in micro, as compared to normo. is not more
labile but is elevated day and night without significant alteration of the
diurnal rhythm. AMBP reflects the association between UAE and blood
pressure more precisely than clinical measurements and may be pref-
erable for identifying candidates for antihypertensive treatment.
A number of studies [1—71 have documented an elevated
office blood pressure level in microalbuminuric type I diabetic
patients, albeit seldom to the level of frank hypertension
according to WHO criteria [81. Experiences during the last two
decades in healthy individuals and patients with essential hy-
pertension have shown that casual blood pressure is not neces-
sarily representative of blood pressure readings throughout a 24
hour period [9]. Ambulatory blood pressure (AMBP) monitor-
ing allows multiple indirect blood pressures to be obtained
while patients are engaged in their normal activities at home or
at work. Several studies in essential hypertensive subjects have
uniformly found that AMBP correlates better with hypertensive
organ lesions (especially left ventricular mass) than casual
blood pressure [10—121, and the only prospective study pub-
lished has demonstrated an improved prognostive value of
AMBP with respect to cardiovascular morbidity and mortality
[13, 14].
Increase in blood pressure is one of the clinical hallmarks of
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diabetic nephropathy [15, 16] and early antihypertensive ther-
apy has improved life expectancy in overt nephropathy dramat-
ically [17]. Blood pressure starts to increase in close relation-
ship to development of persistent microalbuminuria [181, and a
significant correlation exists between annual rate of increase in
urinary albumin excretion (UAE) and blood pressure [5, 19].
Furthermore, intervention studies with antihypertensive ther-
apy in microalbuminuric patients have demonstrated the ability
to arrest or reverse the natural course of increasing UAE
[20—22].
Refined techniques for research or clinical use have been
introduced to secure accurate determination of both kidney
function and subclinical elevations of UAE. Evaluations of
long-term metabolic control are no longer based on occasional
measurements of blood glucose, however, the measurement of
blood pressure still largely depends on casual blood pressures
with well known limitations [23, 241.
The aim of this study was to characterize 24-hour ambulatory
blood pressure pattern in two well-matched groups of normo-
and microalbuminuric type 1 diabetic patients, respectively,
and to relate this to blood pressure obtained in the clinic and to
urinary albumin excretion as a possible marker of the hyper-
tensive load on the kidneys. A group of healthy control persons
was included.
Methods
Patients
Adult outpatients from several centers in Aarhus county
mailed samples of three early morning urine collections to our
laboratory. Microalbuminuria was suspected if urinary albumin
concentration was above 20 ig/ml in more than one sample, and
such patients subsequently collected three timed-overnight
urines within one week. The presence of microalbuminuria was
accepted if UAE was above 20 but below 200 tg/min in more
than one sample.
Thirty-four microalbuminuric (micro.) patients were included
in the study, and for each a normoalbuminuric (normo.) patient
was matched with respect to sex, age and diabetes duration.
Normoalbuminuria was defined as UAE below 20 g/min in
more than one of three overnight urine collections. Healthy
controls recruited among medical students and friends of the
patients were individually matched to their diabetic counterpart
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N
Sex (M/F)
Age years
Diabetes duration years
Body mass index kg/rn2
HbAI,, %
Serum creatinine
p..mol/liter
Insulin dose U/kg
Retinopathy
(normal/background/proliferative)
Smoker (yes/no)
Oral anticonception (yes/no)
Ambulatory monitoring on
working day (yes/no)
Urinary albumin excretion
p.g/min
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34
24/10
30.1 10.3
(19—49)
17.7 6.4
(8—28)
23.9 2.9
(18.9—32.1)
9.1 1.3
(7.2—13.5)
79 13
(53—110)
0.74 0.24
(0.32—1.39)
6/23/5
34
24/10
31.0 10.1
(16—49)
18.0 6.9
(6-31)
23.7 2.6
(19.5—32.4)
8.3 1.5
(5.0—I 1.2)
78 11
(55—100)
0.68 0.17
(0.43—1.05)
23/I i/O
34
24/10
30.5 10.5
(18—53)
for sex and age. AMBP in the micro. patient was measured on
working days or days off as convenient for the patient. Normo.
patients and controls were measured on the same kind of day as
their micro, partner, but strict individual matching was not
possible in two controls.
Inclusion criteria for patients was age <50 years and type 1
diabetes which was defined as a constant need for insulin
treatment since diagnosis before the age of 35 years. Patients
and controls were excluded if they had ever been treated with
diuretics or antihypertensive drugs. No blind, amputated or
pregnant persons were included. One normo. patient was
treated with insulin pump and the rest with one or multiple daily
injections. Clinical data of the patients are shown in Table 1.
All participants were given verbal as well as written instruc-
tions for correct urine sampling, Blood samples were drawn for
measurement of glycosylated hemoglobin HbA1 by HPLC
[251, and serum creatinine (Jaffe's method). Retinopathy was
assessed by funduscopy. Urinary albumin excretion was mea-
sured by radioimmunoassay [26] and overnight specimens were
dipstick tested (Multistix 8SG, Ames, Stokes Court, UK) to
secure nonketonuria and the absence of positive nitrite or
leukocytesterase reaction.
The study was approved by the local ethical committee and
all participants gave their informed consent.
Equipment for blood pressure monitoring
Ambulatory blood pressure was measured by means of a
lightweight (660 g) portable automatic monitor, SpaceLabs model
90202 (Redmond, Washington, USA) using oscillometry [27]. The
monitor was programmed to cuff insufflations every 20 minutes
from 6 a,m. to midnight and every hour during the night.
After demonstration of the equipment and performance of
two measurements for habituation, three oscillometric and
three auscultatory blood pressures were measured on the same
arm while the patient was sitting. The averages of these three
values were named the clinic oscillometric and the clinic
auscultatory blood pressures. All auscultatory measurements
were performed by the same investigator using a random zero
sphygmomanometer (Hawskley and Sons, Lancing, UK) taking
Korotkoff V as diastolic value. If upper arm circumference
exceeded 35 cm (one case) the normal size cuff (12 x 22.5 cm)
was exchanged with a large cuff (15.5 x 38 cm). Oscillometric
measurements were performed with normal and obese arm cuffs
specially designed by the manufacturer.
The patients were asked to note time for going to bed and
rising in the morning and this information was used for calcu-
lating day- and nighttime AMBP as the hourly mean values in
the respective period. The patients were instructed to keep the
arm perfectly still in the phase of deflation, as the equipment is
extremely sensitive to movement in this period; otherwise we
did not attempt to make any standardization with respect to
physical activity. Unclear transducing of signals, mostly be-
cause of arm movements, automatically triggered a remeasure-
ment within two minutes.
Automatic computerized editing of the 24-hour blood pres-
sure report was performed in order to reject readings that most
likely were erroneous. The following criteria were used: sys-
tolic blood pressure >260 or <70 mm Hg, diastolic blood
pressure >150 or <40 mm Hg and heart rate >200 or <20
beats/mm.
Statistical analysis
Parametric statistical analysis was performed whenever pos-
sible. Urinary albumin excretion was logarithmically trans-
formed before any statistical analysis and variability was ex-
pressed as geometric mean x/÷ tolerance factor (antilog of
Table 1. Clinical data of type I diabetic patients and healthy controls studied
Micro- Normo-
albuminuric P albuminuric P Controls
NS
NSb
NS'
<O.O2'
NS
NSL
<0001b
NS"
NS'
NS'
NS
NS"
NSC
NSC
NSC
NSC
19/15
1/9
8/26
23.1 3.2
(18.9—35.0)
5.1 0.59
(3.6—6.2)
82 12
(61—107)
10/24
3/7
lO/24
13/21
1/9
8/26
51.7x/±1.94 — 5.1x/-1.88 NSC 5.2x/÷1.75
(20.2—198.3) (1.1—13.1) (1.6—25.2)
Values are mean SD or geometric mean x/÷ tolerance factor and (range). NS, not significant; analysis of variance; b comparison between
micro- and normoalbuminuric patients; comparison between normoalbuminuric patients and controls.
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Table 2. Clinic and ambulatory blood pressure (oscillometry) in type 1 diabetic patients and healthy controls
Micro-
albuminuric P
Normo-
albuminuric P Controls
Systolic clinic BP mm Hg 131.6 9.1 NS" 127.6 11.6 NSC 124.6 9.8
Systolic day time BP mm Hg 135.9 9.6 <0001b 127.2 9.4 NSC 124.9 9.4
Systolic night time BP mm Hg 122.2 11.4 <00001b 112.0 7.6 NSC 108.6 9.4
Systolic 24 hr BP mm Hg 131.3 9.6 <olydlb 122.4 8.2 NSC 119.2 9.1
Systolic night/day ratio 0.90 0.06 NS 0.88 0.06 NS 0.87 0.05
Diastolic clinic BP mm Hg 78.6 7.4 <0.05" 74.4 8.1 NSC 73.5 7.7
Diastolic daytime BP mm Hg 81.6 7.0 <0.Ol' 77.0 7.0 NSC 76.5 7.2
Diastolic nightime BP mm Hg 69.1 8.2 <0.001" 62.6 6.6 NSC 60.7 7.5
Diastolic 24 hr BP mm Hg 77.5 7.2 <0.01" 72.5 6.1 NS" 71.0 7.0
Diastolic night/day ratio 0.85 0.07 NSb 0.82 0.08 NSC 0.80 0.07
Values are mean sr, N = 34 in each group. NS, not significant; a analysis of variance; b comparison between micro- and normoalbuminuric
patients; "comparison between normoalbuminuric patients and controls.
arithmetic mean and of standard deviation of log transformed
data, respectively). Differences between groups were assessed
by an unpaired t-test only if analysis of variance indicated
significant differences. In cases of nonhomogenity of variance
(Bartlett's test), Kruskall-Wallis test was used and in cases of
significance followed by a Mann-Whitney test. Data within
groups were compared by a paired t-test. Fischers exact test
was used for noncontinuous variables and McNemars test for
paired data. Correlations were calculated as the product-mo-
ment correlation coefficient r. Multiple stepwise regression
analysis was accomplished as a forward selection procedure. P
< 0.05 (two-tailed) was accepted as level of statistical signifi-
cance. All statistical analysis was done by the commercial
available program Statgraphics (STSC, Rockville, Maryland,
USA).
Results
Apart from matching parameters micro. and normo. patients
were compatible with regard to body mass index, insulin dose,
serum creatinine and smoking status. Normo. patients were
comparable to controls also with respect to UAE. HbA, was
significantly higher in micro. (9.1 1.3%) than in normo.
patients (8.2 1.5%; P < 0.02), and retinopathy was more
frequent in micro. patients (P < 0.001).
Auscultatory clinic blood pressure did not differ significantly
between groups. Systolic auscultatory values were: micro. 124
12.0mm Hg, normo. 120.8 13.5 mm Hg and controls 118.7
10.6 mm Hg, However, a tendency towards higher diastolic
auscultatory blood pressure in micro. (81.0 8.8 mm Hg)
compared with normo. patients (76.7 9.7 mm Hg) was noted
(P 0.057), while no difference between norino. patients and
controls (75.3 8.8 mm Hg) was found. Oscillometric clinic
blood pressure values are shown in Table 2.
AMBP revealed a significant elevation of 24 hour, daytime
and nighttime blood pressure in micro. patients compared with
the normo. group, whereas no difference could be found be-
tween normo. patients and controls (Table 2). Similar results
were obtained if the comparison of AMBP was restricted to the
28 micro., 33 normo. patients and 31 controls who had an
auscultatory diastolic clinical value <90 mm Hg. The 24-hour
blood pressure profiles are depicted in Figures 1 and 2.
Diastolic daytime values were significantly higher than clinic
blood pressures in all groups (P < 0.05). The night/day ratios of
systolic blood pressure were comparable between groups, but
significant intergroup differences in diastolic ratio could be
demonstrated by analysis of variance (P <0.02). The night/day
ratio of diastolic blood pressure in micro. was 0.85 0.07,
which was not significantly different from normo. patients: (0.82
0.08, P = 0.09). The 95% confidence interval for the
difference in ratios (micro.-normo.) was from —0.005 to 0.069.
Variability of blood pressure was evaluated as the coefficient
of variation for all systolic measurements in the period (6.00 to
23.00). Values were 9.5 1.8 for micro. 9.2 2.2 for normo.
patients and 9.4 1.8 for controls, without intergroup differ-
ence.
The clinical usefulness of AMBP was also assessed by
plotting daytime diastolic values against clinic oscillometric
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Fig. 1. Twenty-four hour profile of hourly mean systolic and diastolic
blood pressure for microalbuminuric (N = 34, filled circles) and
normoalbuminuric (N = 34, open circles) type 1 diabetic patients.
Vertical bars represent standard errors.
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Fig. 3. Diastolic daytime blood pressure plotted against clinic oscillo-
metric blood pressure for microalbuminuric (N = 34, filled circles) and
normoalbuminuric (N = 34, open circles).
values (Fig. 3). Seven patients (10%) had an oscillometric
diastolic value below 85 mm Hg, but a daytime average above
85 mm Hg (quadrant II); whereas the opposite situation was
present for three patients (quadrant IV; NS).
The prevalence of measurements in the period 6.00 to 23.00
which was above 140 mm Hg systolic or 90 mm Hg diastolic was
assessed. No difference was found between normo. and controls
whereas the prevalence of hypertensive measurements in micro.
significantly outranged that for normo. patients (Table 3).
Ambulatory blood pressure as related to urinary albumin
excretion
Systolic blood pressures (day, night and 24 hour) correlated
significantly with UAE in the pooled diabetic group; the corre-
lation coefficient was 0.45 for daytime values (P < 0.001) and
0.53 for night values (P < 0.0001). In contrast, no significant
correlation was found between auscultatory blood pressure and
UAE (r = 0.21, P = 0.09; Fig. 4). Ambulatory diastolic blood
pressures also correlated with UAE in the combined diabetic
group, but with lower r values (data not shown). In the groups
analyzed separately the only significant correlation found was
between UAE and night blood pressure in normo, patients
(systolic r 0.40, P <0.05).
Also HbA1 and UAE correlated among all diabetic patients
(r = 0.36, P <0.01), but not in subgroups of diabetes.
The multiple stepwise selection was performed in the pooled
diabetic group selecting among the following independent var-
iables: age, diabetes duration, body mass index, HbA1, sex,
smoking, and UAE. The determinants selected are mentioned
in order of significance. With systolic 24-hour blood pressure as
the dependent variable, UAE and sex were identified as the
only independent determinants (R2 = 0.27, P < 0.0001 analysis
of variance for the full regression). The only correlates to
diastolic 24-hour blood pressure were UAE and diabetes dura-
tion (R2 = 0.24, P < 0.001). Correlates with diastolic night
blood pressure in the combined diabetic group were UAE, age
and HbAIC (R2 0.43, P < 0.0001), whereas HbAIC was the
only correlate in the micro, group analyzed separately (R2
0.23, P <0.01).
Multiple stepwise selection was also performed in the pooled
diabetic group with UAE as the dependent variable. In addition
to systolic and diastolic night blood pressure, the possible
independent variables included are listed above. As UAE was
based on overnight samples, only nighttime blood pressures
were assessed as a possible correlate, The night time systolic
blood pressure was the only factor selected as an independent
determinant (R2 = 0.27, P <0.0001).
Ambulatory blood pressure as related to HbAJC
Diastolic and systolic nighttime blood pressure correlated
significantly with HbA1 in diabetic patients (r = 0.42, P <
0.001 and r = 0.31 P <0.01). In diabetic subgroups diastolic
night blood pressure was still clearly correlated to HbAC (r =
0.51, P < 0.01) in micro, but not in normo. patients.
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Fig. 2. Twenty-four hour profile of hourly mean systolic and diastolic
blood pressure for normoalbuminuric type diabetic patients (N 34,
filled circles) and healthy controls (N = 34, open circles). Vertical bars
represent standard errors.
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Table 3. Frequency of daytime (6 .00—23.00) blood pressures in the hypertensive range
Micro- Normo-
albuminuric P albuminuric P Controls
Systolic BP >140 mm Hg %
Diastolic BP >90 mm Hg %
28 (4—90)
16 (0—75)
<0.001"
<0.05"
13 (0—7)
4 (0—57)
NSC
NSC
4 (0—58)
4 (0—55)
Values are median (and range). NS, not significant;
normoalbuminuric patients and controls.
b comparison between micro- and normoalbuminuric patients; ' comparison between
Heart rate
The daytime mean heart rate in micro. patients was signifi-
cantly higher than in normo. patients (88.0 10.0 vs. 82.6
10.1, P < 0.05) and the heart rate in normo. patients was higher
than in controls (75.8 11.1, P < 0.05; Fig. 5). No difference
between micro. (69.1 11.1) and normo. patients (67.1 11.3)
could be found for the heart rate during the night but night heart
rate was higher for normo. patients than controls (59.6 10.2,
P < 0.01). The heart rate decreased about 20% at night with no
intergroup differences.
Calibration
We found a significant difference between the two techniques
for both systolic (P < 1 10— 10) and diastolic blood pressures
(P <0.01; N = 102). The mean systolic difference (oscillometric
— auscultatory) was 6.5 5.9 mm Hg and the mean diastolic
difference was —2.1 7.0 mm Hg. The same results were
obtained if the calibration was evaluated in the group of
controls only.
Discussion
In contrast to previous results, we did not find that blood
pressure was statistically significantly elevated in micro. pa-
tients when measured in the clinic by sphygmomanometry. The
blood pressures in the micro. group in our study, encompassing
only patients without antihypertensive treatment, was consid-
erably lower than previously found, probably reflecting the
recent change in attitude towards early initiation of antihyper-
tensive medication in such patients (Table 4). The use of
Hawskleys random zero sphygmomanometer, necessary to
blind the observer who was aware of the UAE level of the
patients, could contribute as an explanation since this device
has been reported to underestimate blood pressure compared to
ordinary sphygmomanometers [28]. It is still a controversy
whether this underestimation is true or reflects the improved
capability of unprejudiced measurements to recognize the well
known decrement in blood pressure by repeated measurements
on the same occasion in the same patient [291. The higher
ambulatory 24-hour blood pressure measurements in micro.
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Fig. 4. Correlation between UAE (log scale) and (A) systolic clinic blood pressure measured by sphygmomanometry (r = 0.21, P = 0.09) and (B)
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80 100 120 140 160 180
Systolic daytime blood pressure, mm Hg
852 Hansen et al: Ambulatory BP and microalbuminuria
q)
.c
a)4-.t
a)I
100
80
60
Fig. 5. Twenty-four-hour profile of mean hourly heart rate in microal-
buminuric (N = 34, filled circles), normoalbuminuric (N = 34, open
circles) type I diabetic patients and healthy controls (N = 34, open
triangles). Vertical bars represent standard errors.
compared to normo, patients were not due to selection bias as
similar results were found in the subpopulation of patients who
had a diastolic blood pressure below 90 mm Hg when measured
in the clinic. A recent study including 25 diabetic patients with
different degrees of albuminuria reported a significantly ele-
vated ambulatory blood pressure in the diabetic group com-
pared to a control group, but it is not possible to deduce if this
increase was associated with diabetes per seor the presence of
early renal complications in some of the patients [30]. We found
no difference between AMBP in our normo. group as compared
to controls, indicating that elevated AMBP in diabetic patients
without overt nephropathy is a phenomenon closely related to
microalbuminuria, This is in concert with findings indicating
that the prevalence of hypertension is not different in normo.
patients and the background population [31].
HbAIC was higher in micro. patients and elevated AMBP in
these patients could be a consequence of poor glycemic control
rather than early renal dysfunction. This may be supported by
the finding of an independent positive association between
HbA1 and diastolic blood pressure during the night. It can be
speculated that metabolic control might influence the nocturnal
level of pressor active hormones and thus contribute to the
variation of blood pressure unmodulated by physical activity.
However, with respect to 24-hour blood pressure, the multiple
stepwise regression procedure identified UAE as a main deter-
minant and excluded HbAIC as independently influencing the
variation of 24-hour blood pressure. This suggests that in a
cross sectional study, glycemic control is not directly associ-
ated with 24-hour blood pressure beyond the level of an
association between poor glycemic control and microalbumin-
uria, Short term studies have shown increased blood pressure
when glycemic control deteriorates [32, 33]. The possible
impact on 24 hour AMBP awaits similar intervention studies
before this can safely be discussed.
Autonomic function of the diabetic patients was not assessed.
The small but significant elevations of heart rate during the day
in micro, compared with normo. patients as well as in normo.
Table 4. The changing level of blood pressure in microalbuminuric
diabetic patients
Blood
pressure
Year of
publication Number
Mean
age
years
Mean
syst/diast'
mm Hg
Mogensen & Christensen [1] 1984 12 35 138/92
Wiseman et al [2] 1984 12 34 136/87
Mathiessen et al [3] 1984 22 31 131/85
Feldt-Rasmussen et al [4] 1985 34 32 135/86
Christensen & Mogensen [5] 1985 25 27 133/88
Berglund et al [6V' 1987 16 33 135/77
Le Floch et al 171b 1990 23 45 133/77
Present study 1991 34 30 124/81
a Clinic blood pressures by sphygmomanometryb Patients defined as hypertensive excluded from these studies
patients compared to controls are probably explained by auto-
nomic dysfunction [34]. Thus dysautonomia has been already
documented in early stages of diabetic renal disease [35, 361. On
the other hand, we did not recognize a significant difference
between night/day ratios of blood pressure in micro, and
normo. patients as would have been expected if important
differences in autonomic function between the two diabetic
groups were present.
A clinic diastolic blood pressure above 85 mm Hg has been
proposed as a level for introducing antihypertensive therapy
[37]. The main problem of relying on clinic blood pressure in
this category of young and active diabetic patients seemed to be
the risk of underestimating the blood pressure during normal
daily activities. This is in contrast with the problem of "white
coat hypertension" which is a well described phenomenon in
patients with mild essential hypertension, leading to an impor-
tant overdiagnosing of elevated blood pressure [38]. The reason
for this discrepancy is probably that the vast majority of our
patients were normotensive [39]. The frequency of measure-
ments in the hypertensive range (the blood pressure load) has
been suggested as a more precise determinator for hypertensive
organ lesion than a simple daytime or 24 hour average measure-
ment [40]. We found an increased burden of ambulatory blood
pressure measurements above 90 mm Hg in micro. patients
compared with normo. patients though the auscultatory values
in the clinic were comparable. A logical conclusion of these
findings is to recommend the performance of ambulatory blood
pressure in all patient with persistent microalbuminuria.
Guidelines for institution of antihypertensive treatment can-
not be given from the data found in our study. This aspect
awaits results of prospective studies incorporating AMBP and
long-term effects of treating normotensive micro. patients with
angiotensin converting enzyme inhibitors. Meanwhile a certain
level of clinic blood pressure must be accepted as an indication
for initiation of antihypertensive treatment [37]. It may seem
difficult to argue against initiation of treatment in micro. pa-
tients with clinic blood pressures below, but daytime averages
above this level. In fact our finding of a significant correlation
between UAE and daytime average blood pressure, but not
clinic auscultatory blood pressure indicates that AMBP results
could be a more informative parameter of the blood pressure
load on the kidneys, and may serve as a guide for treatment on
1'
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a more relevant pathophysiological basis. Interestingly 'im-
proved' correlations between blood pressure and UAE has also
been found in essential hypertension with application of AMBP
[41—431. As discussed by Coats, such superior correlations
could be a statistical phenomenon related to a reduced day to
day variability of AMBP because of the large number of
measurements [44]. The question of a possible inherent value of
ambulatory measurements as correlates to UAE (and other
variables like left ventricular mass) is interesting, but even if the
improved correlation depends mainly on the multiplicity of
measurements, such are most feasibly obtained in clinical
practice by performing ambulatory rather than clinic measure-
ments.
As UAE was assessed from overnight samples in our study it
is not surprising that we found the highest correlation with night
blood pressures.
Exercise test has shown an exaggerated blood pressure
response in micro, patients and this has been suggested as an
argument for choosing beta blockers in case of antihypertensive
treatment [45]. Our study does not support the idea that daily
life blood pressure in micro. patients should be more labile. We
have found comparable coefficients of variation in blood pres-
sure of the two diabetic groups. On the other hand the increased
heart rate, together with other indications of a hyperkinetic
cardiac function in micro. patients [46], could add to the
discussion on rational adjunct drugs in favor of choosing
cardioselective beta blockers [47].
The SpaceLabs 90202 monitor is one of the presently avail-
able devices which has proved to fulfill the standards of the
American Association for the Advancement of Medical Instru-
ments (AAMI) [27] and has confidently been recommended for
clinical use [48]. Nevertheless, in the range of blood pressures
in this study, we found a significant overestimating of the
systolic blood pressure and underestimating of the diastolic
blood pressure. This does not affect the comparison between
groups with the same range of blood pressures, but our findings
stress the importance of individual calibration [49].
We have previously found a higher reproducibility of 24-hour
blood pressure compared with clinic measurements [50], sug-
gesting that intraindividual changes in blood pressure during
time can be precisely evaluated by AMBP. The optimal param-
eter for monitoring blood pressure in patients at risk for
developing nephropathy may be the individual AMBP changes
over years, combined with changes in UAE, rather than mea-
surement of clinic blood pressure.
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